Venous Thromboembolism – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 

Venous thromboembolism is a blood clot (a thrombus) in the veins related to two conditions: (1) deep vein thrombosis is a clot in a deep vein in the lower leg, thigh, or pelvis, and (2) pulmonary embolism occurs when deep vein thrombosis clot break free from a vein wall, travels to the lungs and block the blood supply. Venous thromboembolism is most likely to occur after major surgery, injury, cancer, heart attack, or heart failure. Redness, swelling, and pain are common symptoms of deep vein thrombosis, whereas pulmonary embolism can include sudden chest pain and shortness of breath. Thrombus formation and propagation depend on abnormalities in blood clotting components, blood vessel wall, and blood flow, known as Virchow's triad. Venous obstruction can result from either external compression by enlarged lymph nodes, bulky tumors, or intravascular compression by the previous thrombosis. Estrogen at the pharmacological level and cancer can also activate the clotting factor.

• Venous thromboembolism affects up to 1 million Americans and >700000 Europeans annually.

 

Thelansis’s “Venous Thromboembolism Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Venous Thromboembolism treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Venous Thromboembolism across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Venous Thromboembolism Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Venous Thromboembolism – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033